Medical Developments International (MVP) H1 2026 earnings summary

Executive summary

• Group revenue increased 8% year-over-year to $21.6 million, driven by 18% growth in Pain Management and a 10% decline in Respiratory, mainly due to softer US demand.

• Positive operating cash flow of $0.3 million, an improvement of $1.0 million from the prior period, with closing cash at $16.9 million.

• Strategic focus on accelerating Penthrox volume growth, margin improvement, and expanding pediatric label in Europe, especially in hospitals.

• Progressed regulatory approvals for pediatric use of Penthrox in Europe, with most country-level approvals expected by August FY26.

• Strengthened commercial and medical initiatives to drive adoption and expand market access.

Financial highlights

• Group revenue up 8% year-over-year to $21.6 million; Pain Management revenue up 18% to $15.4 million, Respiratory revenue down 10% to $6.2 million.

• EBITDA, EBIT, and NPAT slightly down versus prior year, but all improved when excluding FX impacts; EBIT was a $0.3 million loss, NPAT a $0.2 million loss.

• Operating cash flow improved by $1.0 million, reaching $0.3 million; closing cash balance at $16.9 million.

• Free cash flow improved, reflecting disciplined working capital management and lower CapEx.

• Net tangible asset backing per share was 29.6 cents, up from 29.2 cents.

Outlook and guidance

• Expectation of seasonally softer demand and lower earnings in the Respiratory segment for the second half of FY26.

• Anticipate finalizing pediatric indication approvals in Europe and supporting new label launches by August FY26.

• Continued execution of targeted commercial and medical initiatives to expand access and clinical engagement, especially in hospitals.